PetMed Express Shareholders Approve Directors, Pay and Auditor

Petmed Express ( (PETS) ) has provided an update.

At its January 21, 2026 Annual Meeting of Shareholders, PetMed Express reported that 15,506,165 of 21,372,021 eligible shares were represented in person or by proxy, constituting a quorum and allowing the company to conduct official business on the matters presented. Shareholders elected all five board nominees to serve until the next annual meeting, approved on an advisory basis the compensation of the company’s named executive officers, and ratified Baker Tilly US, LLP as the independent registered public accounting firm for fiscal year 2026, reinforcing continuity in governance, executive pay practices, and audit oversight for the company and its stakeholders.

The most recent analyst rating on (PETS) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.

Spark’s Take on PETS Stock

According to Spark, TipRanks’ AI Analyst, PETS is a Neutral.

Petmed Express faces significant financial challenges, with declining revenue and profitability issues. Despite strong technical indicators suggesting bullish momentum, the negative P/E ratio and recent corporate events highlight financial distress. The appointment of new leadership provides a potential positive outlook, but overall, the stock remains risky.

To see Spark’s full report on PETS stock, click here.

More about Petmed Express

PetMed Express operates in the pet healthcare and pharmacy industry, providing prescription and non-prescription medications and related health products for pets, primarily targeting retail pet owners through direct-to-consumer channels in the U.S. market.

Average Trading Volume: 2,669,881

Technical Sentiment Signal: Sell

Current Market Cap: $70.31M

See more insights into PETS stock on TipRanks’ Stock Analysis page.